RTP Mobile Logo
Meet The Professors: Myelodysplastic Syndromes Edition, 2016
Released August 2016

 

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    The myelodysplastic syndromes (MDS) are a diverse group of hematologic disorders associated with ineffective production of myeloid blood cells. Patients with MDS generally experience resultant cytopenias, and their disease also has the significant potential for transformation to acute leukemia, leading to shortened survival. MDS is a disease that primarily affects older adults. Clinical care for the elderly is complicated by the myriad of physical, cognitive and psychosocial changes associated with aging, necessitating that medical oncologists and allied cancer professionals be able to individualize the treatment of these patients.

    To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of advances in this field. Meet The Professors uses relevant case-based discussions between community oncologists and clinical investigators to assist practicing clinicians with the incorporation of this information into their management strategies for MDS.

    LEARNING OBJECTIVES

    • Develop an understanding of the various prognostic scoring systems, and use this information in counseling patients and treatment decision-making.
    • Determine the optimal dosing schedule and treatment duration with azacitidine and decitabine.
    • Appraise the role of bone marrow transplantation for patients with MDS.
    • Evaluate available efficacy and safety data with the use of lenalidomide in patients with low- to intermediate-risk MDS with and without del(5q).
    • Recognize the impact of patient-related factors, including age and cytogenetic abnormalities, on therapeutic planning and potential outcomes.
    • Recall the emerging data with novel agents (eg, checkpoint inhibitors and TGF-beta inhibitors) being investigated in the treatment of MDS.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Harry P Erba, MD, PhD
    Albert F LoBuglio Endowed Chair for Translational Cancer Research
    Chair, SWOG Leukemia Committee
    Professor, Internal Medicine
    Director, Hematologic Malignancy Program
    University of Alabama at Birmingham
    Birmingham, Alabama

    Consulting Agreements: Amgen Inc, ARIAD Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Incyte Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Seattle Genetics, Sunesis Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals, Amgen Inc, Astellas Pharma Global Development Inc, Celator Pharmaceuticals Inc, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board: GlycoMimetics Inc; Speakers Bureau: Celgene Corporation, Incyte Corporation, Novartis Pharmaceuticals Corporation.

    Guillermo Garcia-Manero, MD
    Professor of Medicine
    Chief, Section of Myelodysplastic Syndromes
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No relevant conflicts of interest to disclose.

    COMMUNITY ONCOLOGISTS — The following community oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Warren Brenner, MD
    The Center for Hematology/Oncology
    Lynn Cancer Institute
    Boca Raton, Florida

    Speakers Bureau: Celgene Corporation, Takeda Oncology.

    Neil I Morganstein, MD
    Chair of Leukemia/Lymphoma Board
    Carol G Simon Cancer Center
    Overlook Medical Center
    Summit, New Jersey

    No relevant conflicts of interest to disclose.

    Erik J Rupard, MD
    Chief, Section of Hematology-Oncology
    McGlinn Cancer Institute
    The Reading Hospital and Medical Center
    West Reading, Pennsylvania

    No relevant conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Celgene Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Click below to select videos to play: